Neurocrine Biosciences, Inc.
NBIX
शेयरों में रैंक
#1558
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the... Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
शेयर मूल्य
$137.30
मार्केट कैप
$13.96B
बदलाव (1 दिन)
1.17%
बदलाव (1 वर्ष)
-1.99%
देश
US
व्यापार Neurocrine Biosciences, Inc. (NBIX)
श्रेणी
Healthcare
Neurocrine Biosciences, Inc. (NBIX) के लिए ऑपरेटिंग मार्जिन
October 2026 को ऑपरेटिंग मार्जिन TTM: 23.38%
Neurocrine Biosciences, Inc. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी का वर्तमान ऑपरेटिंग मार्जिन (TTM) 23.38% है। 2023 के अंत में, कंपनी का ऑपरेटिंग मार्जिन 13.30% था।
Neurocrine Biosciences, Inc. के लिए 2000 से 2026 तक ऑपरेटिंग मार्जिन का इतिहास
हर वर्ष के अंत में ऑपरेटिंग मार्जिन
| वर्ष | ऑपरेटिंग मार्जिन | परिवर्तन |
|---|---|---|
| 2026 (TTM) | 23.38% | -3.47% |
| 2024 | 24.22% | 82.11% |
| 2023 | 13.30% | -20.50% |
| 2022 | 16.73% | 85.07% |
| 2021 | 9.04% | -41.98% |
| 2020 | 15.58% | 69.90% |
| 2019 | 9.17% | 12.38% |
| 2018 | 8.16% | -110.04% |
| 2017 | -81.27% | -91.73% |
| 2016 | -982.48% | 106.18% |
| 2015 | -476.51% | 0.00% |
| 2014 | 0.00% | -100.00% |
| 2013 | -1,701.88% | -62,669.12% |
| 2012 | 2.72% | -93.79% |
| 2011 | 43.82% | -206.98% |
| 2010 | -40.96% | -97.75% |
| 2009 | -1,817.47% | -17.24% |
| 2008 | -2,196.18% | -87.33% |
| 2007 | -17,340.03% | 5,903.75% |
| 2006 | -288.82% | 1,326.98% |
| 2005 | -20.24% | -67.06% |
| 2004 | -61.44% | 45.35% |
| 2003 | -42.27% | -92.64% |
| 2002 | -574.20% | 439.66% |
| 2001 | -106.40% | -56.40% |
| 2000 | -244.04% | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के लिए ऑपरेटिंग मार्जिन
| कंपनी | ऑपरेटिंग मार्जिन | ऑपरेटिंग मार्जिन में अंतर | देश |
|---|---|---|---|
| 38.59% | -98.35% |
US
|
|
| -149.01% | -106.37% |
US
|
|
| 25.57% | -98.91% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -98.77% |
NL
|
कंपनी का ऑपरेटिंग मार्जिन क्या होता है?
ऑपरेटिंग मार्जिन किसी कंपनी की लाभप्रदता का मूल्यांकन करने के लिए एक प्रमुख संकेतक है। उच्च ऑपरेटिंग मार्जिनs आम तौर पर बेहतर माने जाते हैं क्योंकि यह दर्शाता है कि कंपनी अपने उत्पादों या सेवाओं को उनकी उत्पादन लागत से कहीं अधिक मूल्य पर बेचने में सक्षम है। इसे कंपनी की कमाई को उसके राजस्व से विभाजित करके गणना किया जाता है।